To investigate the effect of AKT1‐mediated SLC9A6‐126aa phosphorylation in NAFLD, the AKT1 activator SC79 was incubated with AML12 cells transfected with the WT or T77A‐SLC9A6‐126aa plasmid. This evidence concerns the gene SLC9A6 and metabolic dysfunction-associated steatotic liver disease.